WHO Classification of Tumours Editorial Board (2022) WHO classification of tumours series: urinary and male genital tumours. International Agency for Research on Cancer, Lyon (France). https://doi.org/10.32074/1591-951X-838
Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC (2009) Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol 40:1461–1466. https://doi.org/10.1016/j.humpath.2009.02.016
Article CAS PubMed Google Scholar
Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L, Members of the ISUP Bladder Tumor Consensus Panel (2024) International Society of Urological Pathology (ISUP) consensus conference on current issues in bladder cancer. Working Group 2: Grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. Am J Surg Pathol 48:e11–e23. https://doi.org/10.1097/PAS.0000000000002077
Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Ferguson P, Nacey JN (2016) Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation. Histopathology 68:533–540. https://doi.org/10.1111/his.12785
Samaratunga H, Delahunt B (2012) Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology 44:407–418. https://doi.org/10.1097/PAT.0b013e3283560172
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R (2021) Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel) 13:131. https://doi.org/10.3390/cancers13010131
Article CAS PubMed PubMed Central Google Scholar
Barresi V (2018) HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder. Virchows Arch 473:259–260. https://doi.org/10.1007/s00428-018-2394-1
Article CAS PubMed Google Scholar
Vega-Vega A, Simpson F, Samaratunga H, Vega-Garcia A (2020) Pleomorphic giant cell carcinoma of urinary bladder with brain metastases despite initial response to cisplatin and gemcitabine: a case report. Urol Androl Open J 4:46–50. https://doi.org/10.17140/UAOJ-4-133
Yasunaga M, Ohishi Y, Nishimura I, Tamiya S, Iwasa A, Takagi E, Inoue T, Yahata H, Kobayashi H, Wake N, Tsuneyoshi M (2008) Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung. Pathol Int 58:244–248. https://doi.org/10.1111/j.1440-1827.2008.02218.x
Rolim I, Henriques V, Rolim N, Blanca A, Marques RC, Volavsek M, Carvalho I, Montironi R, Cimadamore A, Raspollini MR, Cheng L, Lopez-Beltran A (2020) Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Arch 477:111–120. https://doi.org/10.1007/s00428-020-02745-4
Article CAS PubMed Google Scholar
Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab HS, De Manzoni G, Terzi A, Viale G (2003) Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 27:1203–1215. https://doi.org/10.1097/00000478-200309000-00003
Parwani AV, Herawi M, Epstein JI (2006) Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol 30:1254–1259. https://doi.org/10.1097/01.pas.0000209841.77595.4b
Nigwekar P, Amin MB (2008) The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol 15:218–233. https://doi.org/10.1097/PAP.0b013e31817d79b9
Mosnier JF, Balique JG (2000) Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. Arch Pathol Lab Med 124:135–138. https://doi.org/10.5858/2000-124-0135-PGCCOT
Article CAS PubMed Google Scholar
Lenicek T, Szerda F, Demirovic A, Mijic A, Kruslin B, Tomas D (2007) Pleomorphic ductal carcinoma of the breast with predominant micropapillary features. Pathol Int 57:694–697. https://doi.org/10.1111/j.1440-1827.2007.02159.x
Li X, Zhang Z, Liu J, Wang D, Wei S, Chen J (2018) Molecular features of giant-cell carcinoma of the lung: a case report and literature review. Onco Targets Ther 11:751–756. https://doi.org/10.2147/OTT.S150124
Article PubMed PubMed Central Google Scholar
Bile-Silva A, Lopez-Beltran A, Rasteiro H, Vau N, Blanca A, Gomez E, Gaspar F, Cheng L (2023) Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes. Virchows Arch 482:493–505. https://doi.org/10.1007/s00428-022-03481-7
Article CAS PubMed PubMed Central Google Scholar
Caruso RA, Famulari C, Giuffre G, Mazzeo G (1991) Pleomorphic carcinoma of the gallbladder: report of a case. Tumori 77:523–526. https://doi.org/10.1177/030089169107700615
Article CAS PubMed Google Scholar
Lopez-Beltran A, Blanca A, Cimadamore A, Montironi R, Luque RJ, Volavsek M, Cheng L (2022) T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Arch 480:989–998. https://doi.org/10.1007/s00428-021-03264-6
Article CAS PubMed PubMed Central Google Scholar
Lopez-Beltran A, Amin MB, Oliveira PS, Montironi R, Algaba F, McKenney JK, de Torres I, Mazerolles C, Wang M, Cheng L (2010) Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am J Surg Pathol 34:371–376. https://doi.org/10.1097/PAS.0b013e3181cd385b
Cheng L, Zhang S, Alexander R, Maclennan GT, Hodges KB, Harrison BT, Lopez-Beltran A, Montironi R (2011) Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol 35:e34–e46. https://doi.org/10.1097/PAS.0b013e3182159dec
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG (1998) Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 159:1497–1503. https://doi.org/10.1097/00005392-199805000-00023
Article CAS PubMed Google Scholar
Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran A, Zhou M, Argani P, Delahunt B, Berney DM, Srigley JR, Tickoo SK, Reuter VE, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol 38:1017–1022. https://doi.org/10.1097/PAS.0000000000000254
Lopez-Beltran A, Eble JN, Bostwick DG (2005) Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med 129:683–685. https://doi.org/10.5858/2005-129-0683-PGCCOT
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z (2014) GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 38:13–22. https://doi.org/10.1097/PAS.0b013e3182a0218f
Article PubMed PubMed Central Google Scholar
Akgul M, MacLennan GT, Cheng L (2020) The applicability and utility of immunohistochemical biomarkers in bladder pathology. Hum Pathol 98:32–55. https://doi.org/10.1016/j.humpath.2020.01.004
Article CAS PubMed Google Scholar
Chang A, Brimo F, Montgomery EA, Epstein JI (2013) Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma. Hum Pathol 44:1563–1568. https://doi.org/10.1016/j.humpath.2012.12.012
Article CAS PubMed Google Scholar
Suryavanshi M, Sanz-Ortega J, Sirohi D, Divatia MK, Ohe C, Zampini C, Luthringer D, Smith SC, Amin MB (2017) S100P as a marker for urothelial histogenesis: a critical review and comparison with novel and traditional urothelial immunohistochemical markers. Adv Anat Pathol 24:151–160. https://doi.org/10.1097/PAP.0000000000000150
Comments (0)